Catalog No.
DHD80806
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-nd
Clonality
Monoclonal
Target
Cyclic ADP-ribose hydrolase 1, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase, T10, 2'-phospho-cyclic-ADP-ribose transferase, CD38, ADPRC 1, ADP-ribosyl cyclase 1, 2'-phospho-ADP-ribosyl cyclase
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P28907
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MOR202
Clone ID
MOR202
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial, PMID: 32171061
Emerging agents and regimens for multiple myeloma, PMID: 33168044
CD38 antibodies in multiple myeloma: back to the future, PMID: 29118010
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond, PMID: 29257139
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond, PMID: 26864107
Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma, PMID: 32331242
Immunomodulatory effects of CD38-targeting antibodies, PMID: 29702148
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance, PMID: 30294326
Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway, PMID: 29654274
Combination of lenalidomide and vitamin D enhances MOR202-mediated cytotoxicity of macrophages: It takes three to tango, PMID: 30713598
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma, PMID: 33353443
Reprint of "Immunomodulatory effects of CD38-targeting antibodies", PMID: 30826127
CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers, PMID: 32822558
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience, PMID: 29465271
Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma, PMID: 29756564
CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond, PMID: 32531894
A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys, PMID: 31085699
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance, PMID: 30079070
For research use only. Not for human or drug use.
